Trial Profile
A randomized, placebo-controlled, double-blind, single-dose, dose escalation phase 1b study of lenzilumab in healthy Korean adults
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Lenzilumab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Telcon RF Pharmaceutical
- 05 May 2022 According to a Humanigen media release, first patient dosed in this study.
- 27 Jul 2021 New trial record
- 22 Jul 2021 According to a Humanigen media release, compny plan to apply to MFDS for conditional approval for importation of lenzilumab for use in Korea. Support for conditional approval would be based on data from this phase 1 study and the existing data from Phase 3 LIVE-AIR study. Additional clinical trials are not expected to be necessary in this situation.